Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MBRX vs CNSY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBRX Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–2 Matrix Metrics)

MBRX Overall Winner 6-Pillar Tally: MBRX 4 – 0 CNSY (2 Tie) Matrix Metrics: MBRX 7 – 2 CNSY

As of Nov 16, 2026, Moleculin Biotech, Inc. (MBRX) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBRX carries a Unified Composite Score of 35.5/100 (SELL) at $7.48 (N/M Forward P/E, 0.0% operating margin), whereas CNSY carries 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. MBRX 35.5/100 SELL), MBRX captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: MBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 66.1); meanwhile CNSY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBRX vs CNSY
MBRX NASDAQ Head-to-Head Winner
Moleculin Biotech, Inc.
Pharmaceutical Preparations
$7.48
-4.96% 1D
Market Cap $7.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.61β · 7732% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 24.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (506.4% over 20 days), RSI 66
RSI-14: 66.1 · SMA20: $7.88 · SMA50: $3.49
CNSY US Equity
CNSY
Institutional Equity
$0.72
-24.24% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.54β · 228% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.8%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $1.25 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (MBRX 4 – 0 CNSY)

Columns: Metric · MBRX · CNSY
1. Valuation Multiples MBRX
Forward P/E N/M N/M
Trailing P/E 0.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MBRX
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $7.9M N/A
3. Profitability & Quality MBRX
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -1371.6% N/A
4. Balance Sheet & Cash Flow MBRX
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $10.0M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBRX (7) vs CNSY (2)
Institutional Metric MBRX CNSY Criterion Row Edge
Market Capitalization
Scale
$7.9M N/A Larger Scale MBRX
Trailing P/E Ratio
Valuation
0.0x N/M Lower Multiple MBRX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth MBRX
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin MBRX
Net Profit Margin
Profitability
0.0% N/A Higher Margin MBRX
Return on Equity (ROE)
Capital Efficiency
-1371.6% N/A Higher ROE MBRX
52-Week Range Position
Momentum
73% ($0–$10) 8% ($0–$4) Stronger Trend MBRX
Beta / 30D Volatility
Risk Regime
4.61β · 7732% Vol 2.54β · 228% Vol Lower Realized Risk CNSY
Unified Institutional Score
Composite Signal
35.5 / 100 (SELL) 47.6 / 100 (HOLD) Higher Composite CNSY
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.0M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBRX +2625.27 pp
MBRX: +2567.62% · CNSY: -57.65%
3M Horizon MBRX +1202.66 pp
MBRX: +1126.03% · CNSY: -76.63%
6M Horizon MBRX +1739.55 pp
MBRX: +1660.0% · CNSY: -79.55%
1Y Horizon MBRX +1739.55 pp
MBRX: +1660.0% · CNSY: -79.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBRX vs CNSY. Trailing 12-month operating profitability (MBRX 0.0% vs CNSY N/A) and valuation multiples (MBRX N/M vs CNSY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MBRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1371.6% · N/M
CNSY ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNSY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CNSY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNSY Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBRX vs CNSY Key Questions & Quantitative Answers

As of Nov 16, 2026, Moleculin Biotech, Inc. (MBRX) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBRX carries a Unified Composite Score of 35.5/100 (SELL) at $7.48 (N/M Forward P/E, 0.0% operating margin), whereas CNSY carries 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. MBRX 35.5/100 SELL), MBRX captures the overall institutional head-to-head verdict (7–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: MBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 66.1); meanwhile CNSY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBRX leads the Growth & Scale pillar: MBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CNSY at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MBRX generates N/A in USD-normalized revenue versus N/A for CNSY. In operating R&D and SG&A reinvestment, MBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNSY.

MBRX screens cheaper on headline valuation multiples. MBRX trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CNSY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBRX (-1371.6% ROE) versus CNSY (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, MBRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.61β · 7732% Vol realized risk). By comparison, CNSY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.54β · 228% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.